Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is a gamble if you know little.
OK. See you in a couple of weeks and then re-read your insults.
There are three stages of learning. Knowledge, wisdom & understanding. You haven't begun stage one. Jail-you made my day.
You must decide between opinions and facts.
Nope.
You and the rest don't really comprehend do you. I did not say the monster move comes in 2 weeks-got it? Geez.
Couple more weeks and the rise will happen, no matter what these posters may say.
So are his legal beagles!!
Smart move! Anyone who KNOWS their rights when owning shares in a publicly traded company. Knows that US law states specifically that the financial records are open to scrutiny by said investors as long as they do nothing to harm the company. SEC requires that this info, gleaned from the company, must not be used/traded. See you all when (pharma) inks.
US Open choices:
McIlroy-McDowell-Mahan-Manassero-Molinari.F- TB-269
DROP-news!
MIAMI LAKES, Fla., June 4, 2013 /PRNewswire via COMTEX/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce their Round II Research results have shown their proprietary delivery technology has successfully delivered therapeutic doses of varying-size compounds directly through the epidermis.
During the Company's Round I Research conducted in 2012, caffeine was delivered effectively through the epidermis. This initial study provided four basic principles surrounding Fuse Science's proprietary technology: speed, variability, duration and functionality.
The Round II Research results released May 31, 2013 expanded the prior proof of concepts by showing Fuse's proprietary delivery technology successfully delivering numerous Active Pharmaceutical Ingredients ("API's") of varying size, rigidity and lipophilicity, whether it is fat or water soluble, directly through the epidermis. Nine Fuse Science formulations were tested in an ex vivo penetration study through human epidermis. Eight compounds were tested with the proprietary encapsulation technology and one of them was tested with a second proprietary encapsulation formulation. Fuse Science's proprietary technology delivered Insulin, Paclitaxel, Estradiol, Nicotinic Acid, Folic Acid, Polyethylene Glycol (PEG), Vitamin E Acetate and caffeine with 100% success rate.
Jeanne Hebert, Vice President of Market and Clinical Research of Fuse Science stated, "We are very excited with the recent findings that are providing clear evidence that our delivery technology could be a significant advancement in how medicines, vitamins and nutritional compounds are delivered and absorbed into the human body."
Insulin, one of the compounds previously analyzed, is a reliable proof of principle for the technology. Because it is such a large molecule, and a protein, it has been traditionally very difficult to deliver through the skin unless it was given via an injection. During this study, it passed through even at low concentrations in the Company's proprietary formulation.
In addition, two other large-market drugs Estradiol, used to treat the symptoms of menopause and Paclitaxel, a prescription cancer drug, were tested. It is Fuse's hypothesis, based on the success of their research, that they will be successful in the delivery of therapeutic doses of each, within their matrix, in a simple roll-on application.
The primary benefits that may develop from these studies are:
-- Enhanced delivery option for complex API's
-- Improved bio-availability or enhanced absorption in the body
-- Stronger product efficacy
-- Enhanced ease of use (A simple roll-on application)
-- Expansion of therapeutic options for acute, rapid onset conditions
Data from these preliminary research studies show that with little requirement for optimization, the technology can provide for the transdermal delivery of drugs at clinically relevant doses for the treatment of a wide variety of ailments and diseases. Most compounds showed improvement of delivery over each time-point during the course of the study. The lack of plateaus would suggest that delivery improves with time and can be sustained for periods much greater than twenty-four hours.
This latest research is particularly relevant to the active licensing and M&A efforts of the company.
The full Round II Research report can be found by visiting the "Clinical Research" section of the Fuse Science Investor Relations page here: http://ir.stockpr.com/fusescience/clinical-research.
DROP - radio interview.
http://thestockradio.com/ceo-brian-tuffin-of-fuse-science-inc-otcqbdrop/2756
DROP-8K filing and CC instructions:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9309578
DROP-CC this afternoon just check the latest 8-K filed for instructions. Then read this fantastic news and decide on the bright future.
http://www.bizjournals.com/birmingham/news/2013/05/17/study-expected-to-grow-vision-drug.html
DROP-releases more news.
http://ir.stockpr.com/fusescience/company-news/detail/924
MIAMI LAKES, Fla., May 17, 2013 /PRNewswire via COMTEX/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today that it will hold a business update teleconference and webcast for shareholders and the investment community on Wednesday, May 22nd, 2013 at 4:30 PM ET.
Fuse Science, Inc. CEO, Brian Tuffin will host the call and will be joined by Rubin Hanan, President and COO and Jeanne Hebert, VP of Marketing and Clinical Research. Among the topics the Fuse executives will discuss include; distribution channel progress, third quarter sales growth and marketing updates, and an overview of current developments with the company's science applications.
Interested parties can listen to the live teleconference by dialing (877) 407-0782 from the U.S. or (201) 689-8567 for international callers. Individuals may access the live audio webcast by visiting http://www.investorcalendar.com/IC/CEPage.asp?ID=171023.
A replay of the teleconference will be available until June 5, 2013 which can be accessed by dialing (877) 660-6853 if calling within the United States or (201) 612-7415, if calling internationally. Please enter conference ID # 415071 to access the replay. A replay of the webcast will also be archived and available within the investor relations section of the company's web site at www.fusescience.com.
Read this updated "fact" sheet-no more comment.
http://ir.stockpr.com/fusescience/presentations
Fuse Science has future plans of designing and
developing small hand-held devices, in collaboration with its
scientific team. These devices can conveniently deposit bioactives
to the sublingual and buccal regions in the mouth and are very
compatible with oral physiology, analogous to the common
toothbrush.
Congrats to winner and super job dc!
I try my best to make you rich. You will see come Nov. If the PP comes through the pps will move to a higher base level. From there the team will come with the blitz that will force the 2mm short cover and a surge to .75. There won't be the drama of Tiger's win today.
113.
Right now they are working on three ways for the deal to occur-all depends on which they(counsel) go with. No matter which, the price will be over $4, and shooting for $7-$9.
I buy and hold. Will sell 200k in late Nov-keep the rest till mid Dec. I do my homework and invest. This is a CG play for me not a silly "gamble" playing for $100 or $5k.
You addressed me. This has absolutely no affect on FUSE's future or PPS come next Nov. I don't trade this issue so when you all get the pharma deal-signed & in the SEC filings-you will then understand how & why Tiger signed.
"We've been working extremely hard in establishing the right alliances with strong financial terms to ensure the success of the consumer business."
PowerFuse® and ElectroFuse® Available at Walgreens Nationwide
BY PR Newswire
— 10:49 AM ET 05/09/2013
MIAMI LAKES, Fla., May 9, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce that they have added Walgreens (WAG
Loading...
) as a distribution point for their line of proprietary and innovative consumer products, PowerFuse® and ElectroFuse®.
Initial product distribution began in mid-April at leading Walgreens (WAG
Loading...
) locations near Augusta, Ga. The PowerFuse® and ElectroFuse® four-foot end aisle displays featured Tiger Woods in support of the Masters Golf tournament, and currently showcases NFL All-Pro Arian Foster and Major League Baseball superstar David Ortiz. The next scheduled retail product integration will be in select Walgreens (WAG
Loading...
) stores surrounding the Players Championship Tournament, May 9th – 12th at TPC Sawgrass in Ponte Verde, Fla.
The Fuse Science (DROP
Loading...
) distribution strategy is focused on rolling out their revolutionary consumer products within Walgreens (WAG) locations situated near select PGA tournaments around the country up until, and including, the 2013 U.S. Open in June.
"We are very pleased with the new distribution relationship we have established with Walgreens (WAG
Loading...
)," stated Brian Tuffin, CEO of Fuse Science Inc. "We've been working extremely hard in establishing the right alliances with strong financial terms to ensure the success of the consumer business. We have been very deliberate in our strategy, and continue to make measured progress against our primary objective to build a major national distribution presence for the "Powered By Fuse®" brands. This distribution agreement, and others we expect to announce in the future, reflects a milestone for the retail distribution of our products that we believe will set the stage for the ramp-up of revenue generation and substantial growth of Fuse Science (DROP
Loading...
)," concluded Tuffin.
PowerFuse® and ElectroFuse® are Fuse's revolutionary consumable DROP products, which deliver "All The Energy You Need In A Single Dropâ„¢" and "All The Electrolytes You Need In A Single Dropâ„¢." Both products can be found on Walgreens.com and Drugstore.com.
About Fuse Science (DROP
Loading...
), Inc.
Fuse Science, Inc. (DROP
Loading...
) , is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science (DROP
Loading...
) holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science (DROP
Loading...
) technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science (DROP
Loading...
) is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).
For Fuse news as it happens, follow @Fuse_Science (DROP
Loading...
) on Twitter and Like Us on Facebook!
You can post all the FACTS you want on this thread and it won't mean a thing to the 304 readers-90% of which are traders/flippers. I could care less about subjective opinions given here as 15Nov13 is the day of reckoning. Buy-hold-wait-then sell.
He is a disgruntled X that the company knows. So ignore all of his posts, like I do, and you will enjoy the profits from owning DROP.
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTIONS 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended September 30, 2012
Commission File Number 000-22991
Fuse Science, Inc.
You know FUSE has proved commitment to these distributors that they will/are spending time & money to promote their products. The explosive great news will come just before the 3rd quarter.
Yes. People have to try a product 1st to know if it works and then they have to evaluate whether the cost is in their budget. The seller still clears $4 at the lower price.
Garcia-Day-D.Johnson-Mcdowell-Snedeker-274
Both are LA persons of notoriety. They were chosen for very good reasons and will only help expand the consumer base and ad programs coming up. I'm a Gomez fan/Baffert but don't follow TV/Hollywood glitz.
Your posts should be READ as they are balanced, informative and accurate. Thanks.
A significant filing which affects all investors and the following day a PR.
Why hasn't there been any real discussion about the amended S-1 filing?
The S-1A today has the same ~$10mm you stated. Obvious you are inside. Too bad-it has been sent to the SEC for review.
Q coming 15May with all the numbers.
Can't answer your questions. You did not make a mistake in buying.